Potential inhibitors of the PI-3K–AKT–mTOR pathway, which is frequently dysregulated in cancer (41), are expected to have therapeutic utility in many tumors, and several of these inhibitors are under current investigation as therapeutic agents for cancer (42). This evidence concerns the gene AKT1 and cancer.